Drugs / PF-08046037
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06974734 | May 2025 → Mar 2026 | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Pfizer | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046037 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06974734 ↗ |
| Route | Intravenous | “PF-08046037 alone as an intravenous (IV) infusion (given directly into a vein)” NCT06974734 ↗ |